{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-127067","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.650218+00:00","generated_at":"2026-05-30T00:14:11.728591+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Plus Therapeutics Q3 net loss $9.1M, cash $4.8M; FDA clears Phase 1 LM trial","bullets":["Net loss YTD Sep 30, 2024: $9.1M ($1.46 basic EPS) vs $9.5M ($3.54) prior year; operating loss $10.8M vs $9.5M.","Cash and investments $4.8M at Sep 30, down from $8.6M at Dec 31, 2023; subsequent $0.9M DoD grant, $3.9M CPRIT grant expected.","FDA agreed to initiate Phase 1 multi-dose trial of Rhenium(186Re) Obisbemeda for leptomeningeal metastases (LM); enrollment starts early 2025 at 7 U.S. sites.","Completed enrollment in ReSPECT-GBM Phase 1 trial; presented positive data at CNS 2024; expanded sites to North Shore and Ohio State.","Established GMP manufacturing partnership with SpectronRx for late-stage clinical and commercial supply of Rhenium(186Re) Obisbemeda."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-127067","json":"https://secwatch.observer/filing/0000950170-24-127067.json","markdown":"https://secwatch.observer/filing/0000950170-24-127067.md","text":"https://secwatch.observer/filing/0000950170-24-127067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000095017024127067/0000950170-24-127067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000095017024127067/pstv-20241114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:14:11.728591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}